Sean Laaman

Stock Analyst at Morgan Stanley

(4.73)
# 124
Out of 5,090 analysts
18
Total ratings
88.24%
Success rate
22.62%
Average return

Stocks Rated by Sean Laaman

MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $17.90
Upside: +89.94%
Exelixis
Nov 5, 2025
Maintains: Overweight
Price Target: $44$45
Current: $44.16
Upside: +1.90%
Axsome Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $194$196
Current: $151.04
Upside: +29.77%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90$115
Current: $95.00
Upside: +21.05%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298$304
Current: $254.78
Upside: +19.32%
BeOne Medicines AG
Oct 20, 2025
Maintains: Overweight
Price Target: $350$383
Current: $318.74
Upside: +20.16%
Certara
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $16
Current: $9.48
Upside: +68.78%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3$1.5
Current: $1.20
Upside: +25.00%
Halozyme Therapeutics
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $63.48
Upside: +5.55%